Young Investigator Award (YIA) Abstract Policies and Procedures

General Information

- All abstract presentations and question-and-answer periods will be in English.
- Full text of the abstracts will be viewable beginning Monday, March 25, 2024, at 8 a.m. Eastern Time.
- Investigators need not be ACC members to participate.
- All accepted abstract presenters must register for ACC.24. Individuals should register in the appropriate category (member, nonmember, etc.) and pay the applicable fees for the registration category. Registration will open in September, so please monitor the ACC.24 registration site.
- Submitting authors will be notified via email by Wednesday, Sept. 27, 2023 regarding acceptance disposition.
- General Information subject to change due to circumstances beyond the ACC’s control.

Policies

- YIA Abstracts must be SUBMITTED BY 1 p.m. ET on Tuesday, Sept. 5, 2023. The American College of Cardiology is not responsible for abstracts that are not submitted by this deadline date.
- Submissions with “INCOMPLETE” status cannot be processed.
- Submission of an abstract constitutes a commitment by the author(s) to present if accepted. Failure to present and register for the meeting, if not justified, will jeopardize future acceptance of abstracts.
- There is no limit to the number of abstracts an investigator may submit. If selected, the presenter must be one of the co-authors listed.
- The presenting author should be the submitting author.
- Investigators should not submit the same research; abstracts that appear to be replicate versions of a single study will be rejected. Submissions will be checked for duplication and replicate versions will be rejected.
- Abstracts not accepted as YIA abstracts may be submitted by the author as regular abstracts during the abstract submission process (Aug. 23 – Oct. 12, 2023).
- Follow all instructions for completing the submission. Be sure to structure the content into Background, Methods, Results, and Conclusion sections.
- Clarity of expression will be considered in the review process. The overall quality of language used should assure comprehension by the reader.
- Use a maximum of five unique abbreviations in the body of the abstract. No abbreviations should appear in the title. Place abbreviations in parentheses after the full word the first time it appears. Abbreviations increase the difficulty of reading and evaluating abstracts, which will be considered in the review process.
- If authors’ names appear on more than one abstract, their names must appear and be spelled identically on each abstract in order to facilitate proper indexing. Whenever possible, do not list authors with initials only.
• Submitters may return to the online system to edit abstracts, revise information, correct typographical errors, tables, graphics, or delete a submission at any time before 1 p.m. ET on Sept. 5, 2023. After this time, the system will be closed, and “Complete” abstracts will be forwarded for the reviewing process.

• An author may not revise or resubmit an abstract in order to make changes or corrections after this deadline; adding or removing authors after the submission deadline is not permitted. The abstract may be withdrawn or, if accepted, the error may be indicated during the presentation.

• Proofread abstracts carefully to avoid errors before they are submitted. The ACC is not authorized to make changes to a submission. This includes typographical errors. Your abstract, if selected, will be published exactly as submitted. Tables and graphics, if the quality submitted is poor, will also appear badly.

• If you choose to withdraw an abstract after the submission deadline, this request must be received by the ACCF in writing and sent to awards@acc.org by Wednesday, Jan. 10, 2024. After this date, withdrawals are still accepted but abstracts may still appear in publications.

• Abstracts are not eligible for consideration if the research has been accepted for presentation at another U.S. national meeting or international meeting prior to ACC.24 or published in another journal prior to the embargo time set by the ACC.

• Any human experimentation must conform to the principles of the Declaration of Helsinki of the World Medical Association.

• The Program Committee endorses the position of the American Association for the Advancement of Science in requiring assurances of the responsible use of animals in research. All submissions for consideration must be in compliance with the guidelines.

• Abstracts will be considered “complete” without completed disclosures and will go to review as long as all submission elements are complete. The presenter and lead investigator must disclose by Friday, March 1, 2024. Failure to provide disclosure information will result in the removal of an accepted abstract from the program. Disclosure information is submitted via the ACC Disclosure System (https://disclosures.acc.org).

• ACC will create a disclosure slide for oral presenters displaying disclosure information of the presenting author and lead investigator based on the disclosure information submitted to the ACC Disclosure System.

• On behalf of all co-authors, the submitting author/investigator agrees that the submission of an abstract constitutes the submitting author and all co-authors’ agreement to assign and transfer to the American College of Cardiology (“ACC”) all rights, title and interest, including copyright and all rights subsumed thereunder, in and to the abstract and all material contained therein if the abstract is accepted. Except as otherwise set forth herein, the American College of Cardiology, as holder of the copyright on the accepted abstract, reserves all rights of reproduction, distribution, performance, display, and the right to create derivative works in both print and digital formats. The assignment of copyright to ACC shall be required for, and the terms set forth in this section shall apply to, abstracts submitted or presented in any format, including live, hard copy, or digital formats.

• On behalf of all co-authors, the submitting author/investigator agrees that the presentation of an abstract at or in connection with ACC.24 constitutes the submitting author and all co-authors’ agreement to assign and transfer to the American College of Cardiology (“ACC”) all rights, title and interest, including copyright and all rights subsumed thereunder, in and to the presentation and all material contained therein. Except as otherwise set forth herein, the American College
of Cardiology, as holder of the copyright on the accepted abstract, reserves all rights of reproduction, distribution, performance, display, and the right to create derivative works in both print and digital formats. The assignment of copyright to ACC shall be required for, and the terms set forth in this section shall apply to, presentations in any format, including live, digital, or virtual formats.

- ACC hereby grants to the submitting author/investigator and the co-authors a non-exclusive, limited, non-transferable license to use the abstract and presentation and all content contained therein for educational, scientific, and research purposes, provided, however, that such license shall only be effective and such use is only permitted following the conclusion of ACC.24 and after any embargoes in place on ACC.24 content have been removed. Such license does not include the right for the authors or any sponsors to provide links to, or copies of, the abstract or presentations to third parties or ACC.24 attendees in advance of or during ACC.24. Notwithstanding, the authors are permitted to include a link to the abstract in the author’s presentation.
- All abstracts submitted in connection with ACC.24 and are disclosed to members of the peer review selection committee, as well as to ACC employees and contractors as necessary.
- Titles, authors, up to two institutions and presentation time information of accepted abstracts will be available online in advance of the Scientific Session. Full text of the abstracts will be viewable online and distributed to all professional registrants onsite. Abstracts not accepted for presentation are not published and will not be disclosed outside of ACC and persons associated with the selection process (e.g., the peer review committee).
- Although ACC and ACC employees or contractors cannot guarantee the confidentiality of submitted abstracts, every effort will be made to ensure confidentiality of submitted material.
- Primary responsibility for compliance with any disclosure or nondisclosure requirements resides solely with researchers and/or research sponsors.
- In light of increased attention to how research results (particularly those affecting the stock of publicly-traded companies) are released publicly, the American College of Cardiology (ACC) is clarifying its policies governing the disclosure of scientific research results contained in late-breaking clinical trial presentations and abstracts. Please read the Media & Communications Policies carefully. Anyone determined by the College to have violated the embargo policies may be withdrawn from the program or sanctioned as deemed necessary.

In the event that an author’s/presenter’s work will be published in a major peer reviewed medical journal concurrent with the timing of the Annual Scientific Session, it is the responsibility of the abstract author/presenter to notify the ACC press office of the publication name and date as soon as possible. Doing so will allow ACC to work with the publication to coordinate embargo of the material.

Accepted Abstracts

Titles, authors, up to two institutions and presentation time information of accepted abstracts will be posted in the online/mobile searchable program planner systems beginning Monday, March 25, 2024, at 8 a.m. ET when the embargo lifts. Full text of accepted abstracts will be published in JACC online on Thursday, April 4, 2024.